Antogen, an emerging life sciences tools and diagnostics company, announced the completion of a seed financing round led by iGrow Venture Partners, with participation from a select group of life sciences angel investors.
The funding will support continued development of Antogen’s proteomics platform, advanced machine learning models, and proprietary biological datasets, while expanding the company’s scientific and operational capabilities. The company has already established early commercial traction through its contract research services and plans to accelerate customer engagement and platform growth.
Founded by Zachary Antovich, Antogen is developing a novel approach to immune surveillance with potential applications across multiple clinical care settings. Antovich previously founded and served as chief executive officer of Linkage Biosciences, a diagnostics company that built a global commercial footprint before being acquired by Thermo Fisher Scientific.
According to the company, the new capital will help advance its efforts to create a new class of research tools and diagnostics designed to improve patient care and health outcomes. Antogen is supported by a syndicate of investors and is led by a team of experienced life sciences innovators.
iGrow Venture Partners is a growth-focused venture capital firm investing in early-stage technology companies across Europe and the United States. The fund is backed by institutional investors and family offices with expertise across multiple sectors.
KEY QUOTE:
“Antogen brings together experienced leadership, strong scientific foundations, and a clear opportunity to serve emerging needs in immune monitoring. We are pleased to lead this financing and support Zachary and the Antogen team as they build on the company’s early progress.”
Anastasios Economou, Partner, iGrow Venture Partners
